You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-mesothelin CAR-T

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mesothelin-positive Advanced Malignant Solid Tumors Trial (Anti-mesothelin CAR-T cells)

Not yet recruiting
  • Mesothelin-positive Advanced Malignant Solid Tumors
  • Anti-mesothelin CAR-T cells
  • (no location specified)
Mar 13, 2023

Mesothelin-positive Advanced Malignant Solid Tumors Trial in Hangzhou (UCLM802 Cell Injection (Anti-mesothelin CAR-T cells))

Recruiting
  • Mesothelin-positive Advanced Malignant Solid Tumors
  • UCLM802 Cell Injection (Anti-mesothelin CAR-T cells)
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital Zhejiang University School of Medi
May 11, 2023

Solid Tumor Trial (UCLM802 Cell Injection)

Not yet recruiting
  • Solid Tumor
  • UCLM802 Cell Injection
  • (no location specified)
Mar 7, 2023

Refractory Malignant Solid Tumor Trial in Shanghai (anti-MESO CAR T cells)

Recruiting
  • Refractory Malignant Solid Neoplasm
  • anti-MESO CAR T cells
  • Shanghai, China
    Department of Oncology, Ruijin Hospital
Sep 16, 2021

Pancreas Cancer, CAR-T Cell Therapy, Mesothelin Trial in Guangzhou (CAR-T cells)

Recruiting
  • Pancreas Cancer
  • +3 more
  • CAR-T cells
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Mar 10, 2023

Pancreatic Cancer Trial in Shatin (MSLN CART)

Not yet recruiting
  • Pancreatic Cancer
  • MSLN CART
  • Shatin, N.t., Hong Kong
    Endoscopy Centre, Prince of Wales Hospital
Sep 19, 2023

Breast Cancer Trial in Philadelphia (huCART-meso cells, Mesothelin Expression Testing)

Not yet recruiting
  • Breast Cancer
  • huCART-meso cells
  • Mesothelin Expression Testing
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Jan 5, 2023

Solid Tumor, Adult Trial in Beijing (anti-mesothelin CAR-T cells)

Unknown status
  • Solid Tumor, Adult
  • anti-mesothelin CAR-T cells
  • Beijing, China
    Biotherapeutic Department and Hematology Department of Chinese P
Aug 6, 2020

Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma Trial in Philadelphia (huCART-meso cells)

Recruiting
  • Lung Adenocarcinoma
  • +5 more
  • huCART-meso cells
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Dec 1, 2022

Carcinoma Trial (Intravenous infusion anti-CEA-CAR-T cell)

Not yet recruiting
  • Carcinoma
  • Intravenous infusion anti-CEA-CAR-T cell
  • (no location specified)
Aug 22, 2023

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti Tim-3/CD123 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 4, 2023

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant Trial (SynKIR-110, Autologous T cells Transduced with

Not yet recruiting
  • Ovarian Cancer
  • +2 more
  • SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
  • (no location specified)
Oct 5, 2022

Solid Tumor Trial in Shenyang (Intravenous infusion anti-HER2-CAR-T cell)

Not yet recruiting
  • Solid Tumor
  • Intravenous infusion anti-HER2-CAR-T cell
  • Shenyang, Liaoning, China
    Phase I Clinical Trials Center Of The First Hospital of China Me
Oct 30, 2023

CD70-positive Advanced Urologic Tumors Trial in Shanghai (Anti-CD70 CAR-T cells)

Recruiting
  • CD70-positive Advanced Urologic Neoplasms
  • Anti-CD70 CAR-T cells
  • Shanghai, Shanghai, China
    Changhai Hospital
Aug 11, 2023

Acute T-lymphoblastic Leukemia, Acute T-lymphoblastic Lymphoma Trial in Xuzhou (CAR-T Cell Infusion)

Recruiting
  • Acute T-lymphoblastic Leukemia
  • Acute T-lymphoblastic Lymphoma
  • CAR-T Cell Infusion
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023

Lung Cancer, Cancer, Immunotherapy Trial in Guangzhou (CAR-T cells targeting PSCA, MUC1, TGFß, HER2, Mesothelin, Lewis-Y, GPC3,

Recruiting
  • Lung Cancer
  • +3 more
  • CAR-T cells targeting PSCA, MUC1, TGFβ, HER2, Mesothelin, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2, or B7-H3
  • Guangzhou, Guangdong, China
  • +1 more
Nov 26, 2021

B-cell Non Hodgkin Lymphoma Trial in Xuzhou (regimen with BTK inhibitor +Anti-CD19 CAR T cells)

Recruiting
  • B-cell Non Hodgkin Lymphoma
  • regimen with BTK inhibitor +Anti-CD19 CAR T cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023

B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors Trial in Kunming (Anti-CD19 Autologous CAR-T Cell Infusion)

Recruiting
  • B-Cell Leukemia
  • +2 more
  • Anti-CD19 Autologous CAR-T Cell Infusion
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Jul 9, 2023

B-cell Lymphoma Trial in Xuzhou (ASCT+CAR-T Cell Infusion)

Recruiting
  • B-cell Lymphoma
  • ASCT+CAR-T Cell Infusion
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023

Metastatic Pancreatic Carcinoma Trial in Providence (CAR2 Anti-CEA CAR-T cells)

Terminated
  • Metastatic Pancreatic Carcinoma
  • CAR2 Anti-CEA CAR-T cells
  • Providence, Rhode Island
    Roger Williams Medical Center
Jan 12, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Anti-GPRC5D CAR-T Cells Injection)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Anti-GPRC5D CAR-T Cells Injection
  • (no location specified)
Feb 18, 2023

SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)

Recruiting
  • SLE (Systemic Lupus)
  • +4 more
  • CD19 targeted CAR-T cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Sep 25, 2023

Advanced Breast Cancer, Breast Tumor Malignant Female Trial in Guangzhou (AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells)

Completed
  • Advanced Breast Cancer
  • Breast Neoplasm Malignant Female
  • AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Apr 11, 2023

Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Anti-CD33 CAR

Not yet recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Anti-CD33 CAR T-cells
  • Lymphodepletion Therapy
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023